Findings
What does this study add?
- Mean age was 57.1 years, mean baseline HbA1C was 8.6% and mean body weight was 95.7 kg.
- At 36 weeks, decreases in HbA1c with dulaglutide 1.5 mg, 3 mg, and 4.5 mg were -1.53%, -1.71%, and -1.87%, respectively.
- At 36 weeks, decreases in body weight with dulaglutide 1.5 mg, 3 mg, and 4.5 mg were -3.1 kg, -4.0 kg, and -4.7 kg, respectively.
- At 36 weeks, decreases in fasting plasma glucose with dulaglutide 1.5 mg, 3 mg, and 4.5 mg were -44.2 mg/dL, -47.9 mg/dL, and -52.3 mg/dL, respectively.
- Dulaglutide 3 mg and 4.5 mg were both superior to dulaglutide 1.5 mg at the 36-week primary endpoint, and remained significantly superior at 52 weeks, for improvements in measures of glycemic control and body weight.
- As expected for the GLP-1 receptor agonist class, commonly reported adverse events were nausea, diarrhea, and vomiting.
- There were no new safety findings with the higher dulaglutide doses.